RVTY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now for a tactical entry. RVTY is sitting near a key support pocket (S2 105.3) after a pullback, RSI is near oversold, and Street price targets cluster modestly above the current price ($107 vs. $110–$115). While short-term momentum is weak (bearish MACD), the bigger-picture moving-average stack remains bullish (SMA_5 > SMA_20 > SMA_200), creating a reasonable “buy-the-dip near support” setup for an impatient buyer targeting a rebound toward ~$112 (pivot).
Price/levels: RVTY ~$107.17 is below S1 (108.10) and just above S2 (105.30), which is a typical bounce zone if buyers defend support. Trend: Longer-term trend bias is still constructive given bullish moving averages (SMA_5 > SMA_20 > SMA_200), but short-term momentum is currently bearish. Momentum: MACD histogram is negative (-0.726) and expanding lower, signaling downside momentum is still active. RSI(6) ~31.6 is close to oversold conditions, often consistent with late-stage selling pressure and potential for a reflex bounce. Path of least resistance: Near-term rebound target is pivot ~112.63; failure to hold ~105.30 would negate the “support bounce” thesis.
Technical location: trading near S2 (~105.
with RSI near oversold increases odds of a short-term bounce.
Analyst setup narrative for 2026 Tools: multiple firms see improving end markets and sector rotation tailwinds.
Options flow today is call-skewed (volume P/C 0.11), suggesting bullish near-term trader sentiment.
Upcoming earnings (QDEC 2025 on 2026-02-02 pre-market) can act as a catalyst if results/guide beat expectations (Est. EPS 1.55).
Momentum is still deteriorating (MACD negative and expanding), so the dip can extend before stabilizing.
Fundamentals: profitability compression in the latest reported quarter (Q3
with sharp YoY declines in net income and EPS plus lower gross margin.
Elevated implied volatility (high IV percentile) reflects meaningful uncertainty into the next event window (earnings).
No supportive news flow in the last week; absent a catalyst, price can continue to drift with market risk-off.
Latest quarter (2025/Q3): Revenue grew to $698.95M (+2.18% YoY), but profitability weakened materially—Net Income $46.65M (-50.56% YoY) and EPS $0.40 (-48.05% YoY). Gross margin fell to 53.6% (-4.73% YoY). Net takeaway: top-line growth is positive but slow, while margins/earnings are trending down, which is the main fundamental overhang until margins stabilize.
Recent trend: Mostly constructive but mixed. Evercore maintained Outperform and raised PT to $112 (from $108). Barclays reiterated Overweight and raised PT to $115 (from $105). Wells Fargo kept Equal Weight and raised PT to $107 (from $102). Counterbalance: BofA downgraded to Neutral (PT $110) and Goldman initiated at Neutral (PT $105) citing cautious timing on recovery in some end markets. Wall Street pros: improving end markets/rotation into Tools and a better 2026 setup. Cons: uncertainty around the timing of recovery (drug discovery, academic/government spend) and evidence of recent margin/EPS pressure.
